RS50568B8 - Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze - Google Patents

Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze

Info

Publication number: RS50568B8
Authority: RS; Serbia
Prior art keywords: inhibition; compounds; methods; aurora kinase; mitotic progression
Prior art date: 2004-05-14

Application number

RS20080109A

Other languages

English (en)

Inventor

Christopher F Claiborne

Lloyd J Payne

Richard J Boyce

Todd B Sells

Stephen G Stroud

Stuart Travers

Tricia J Vos

Gabriel S Weatherhead

Original Assignee

Millennium Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-14

Filing date

2005-05-12

Publication date

2019-08-30

2005-05-12 Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc

2010-05-07 Publication of RS50568B publication Critical patent/RS50568B/sr

2019-06-28 Publication of RS50568B9 publication Critical patent/RS50568B9/sr

2019-08-30 Publication of RS50568B8 publication Critical patent/RS50568B8/sr

Links

102000003989 Aurora kinases Human genes 0.000 title 1
108090000433 Aurora kinases Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
230000008600 mitotic progression Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)
Small-Scale Networks (AREA)

RS20080109A 2004-05-14 2005-05-12 Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze RS50568B8 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US57165304P	2004-05-14	2004-05-14
US61722104P	2004-10-08	2004-10-08
EP05779921A EP1771450B9 (en)	2004-05-14	2005-05-12	Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
PCT/US2005/016445 WO2005111039A2 (en)	2004-05-14	2005-05-12	Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Publications (3)

Publication Number	Publication Date
RS50568B RS50568B (sr)	2010-05-07
RS50568B9 RS50568B9 (sr)	2019-06-28
RS50568B8 true RS50568B8 (sr)	2019-08-30

Family

ID=35262144

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20080109A RS50568B8 (sr)	2004-05-14	2005-05-12	Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
RS20120416A RS52436B (sr)	2004-05-14	2005-05-12	Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20120416A RS52436B (sr)	2004-05-14	2005-05-12	Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze

Country Status (25)

Country	Link
US (9)	US7572784B2 (sr)
EP (4)	EP2719698B1 (sr)
JP (4)	JP4467616B2 (sr)
KR (3)	KR101792651B1 (sr)
CN (1)	CN104193750B (sr)
AR (1)	AR049277A1 (sr)
AT (1)	ATE381566T1 (sr)
AU (1)	AU2005243175B2 (sr)
BR (1)	BRPI0511139B8 (sr)
CA (1)	CA2565411C (sr)
CY (2)	CY1108092T1 (sr)
DE (1)	DE602005003951T4 (sr)
DK (1)	DK1771450T5 (sr)
EA (1)	EA012112B1 (sr)
ES (3)	ES2540987T3 (sr)
HR (2)	HRP20080120T5 (sr)
IL (1)	IL179063A (sr)
MX (1)	MXPA06013042A (sr)
MY (1)	MY139355A (sr)
NZ (1)	NZ551370A (sr)
PL (1)	PL1771450T3 (sr)
PT (2)	PT1771450E (sr)
RS (2)	RS50568B8 (sr)
TW (1)	TWI338688B (sr)
WO (1)	WO2005111039A2 (sr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005243175B2 (en) *	2004-05-14	2011-12-01	Millennium Pharmaceuticals, Inc.	Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CN102766142A (zh) *	2004-10-04	2012-11-07	千禧药品公司	有效作为蛋白激酶抑制剂的内酰胺化合物
AR051467A1 (es) *	2004-10-29	2007-01-17	Banyu Pharma Co Ltd	Derivados de aminopiridina con accion inhibitoria selectiva de la aurora quinasa a
AU2006241825A1 (en)	2005-04-28	2006-11-09	Mitsubishi Tanabe Pharma Corporation	Cyanopyridine derivative and use thereof as medicine
AU2006243000B2 (en) *	2005-05-05	2011-05-26	Macrophage Pharma Limited	Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
US8624027B2 (en) *	2005-05-12	2014-01-07	Abbvie Inc.	Combination therapy for treating cancer and diagnostic assays for use therein
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7572809B2 (en) *	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
EP1978964A4 (en) *	2006-01-24	2009-12-09	Merck & Co Inc	JAK2 tyrosine kinase Inhibition
EP1994022A2 (en) *	2006-03-15	2008-11-26	Wyeth a Corporation of the State of Delaware	N-substituted-azacyclylamines as histamine-3 antagonists
CN101405001A (zh) *	2006-03-20	2009-04-08	霍夫曼-拉罗奇有限公司	抑制btk和syk蛋白质激酶的方法
CN101432261A (zh) *	2006-05-19	2009-05-13	惠氏公司	作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
US7718648B2 (en)	2006-08-09	2010-05-18	Millennium Pharmaceuticals, Inc.	Pyridobenzazepine compounds and methods for inhibiting mitotic progression
PE20081152A1 (es) *	2006-10-06	2008-08-10	Wyeth Corp	Azaciclilaminas n-sustituidas como antagonistas de histamina-3
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
EP2073807A1 (en)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmaceutical combinations
CL2007003244A1 (es)	2006-11-16	2008-04-04	Millennium Pharm Inc	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AU2012203952B2 (en) *	2006-11-16	2014-12-11	Millennium Pharmaceuticals, Inc.	Compounds for inhibiting mitotic progression
AU2014280932B2 (en) *	2006-11-16	2016-10-06	Millennium Pharmaceuticals, Inc.	Compounds for inhibiting mitotic progression
CN101778838A (zh) *	2007-05-24	2010-07-14	惠氏有限责任公司	作为组胺-3拮抗剂的氮杂环基苯甲酰胺衍生物
TW200914457A (en) *	2007-05-31	2009-04-01	Kyowa Hakko Kogyo Kk	Pyrimidodiazepinone derivative
CA2693138A1 (en) *	2007-07-16	2009-01-22	Wyeth Llc	Aminoalkylazole derivatives as histamine-3 antagonists
AU2008294535A1 (en) *	2007-09-04	2009-03-12	Biolipox Ab	BIS-aromatic compounds useful in the treatment of inflammation
WO2009036144A1 (en) *	2007-09-12	2009-03-19	Wyeth	Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
TW200918062A (en) *	2007-09-12	2009-05-01	Wyeth Corp	Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
JP2009108036A (ja) *	2007-09-28	2009-05-21	Fujifilm Corp	新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物
JP5555186B2 (ja) *	2008-02-29	2014-07-23	クロマセラピューティクスリミテッド	ｐ３８ＭＡＰキナーゼ阻害剤
GB0803747D0 (en) *	2008-02-29	2008-04-09	Martin	Enzyme and receptor modulation
CN102014627B (zh)	2008-04-30	2014-10-29	国家卫生研究院	作为极光激酶抑制剂的稠合双环嘧啶化合物
US20110112193A1 (en) *	2008-05-14	2011-05-12	Peter Nilsson	Bis-aryl compounds for use as medicaments
JP5684719B2 (ja) *	2008-12-05	2015-03-18	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
RU2535032C2 (ru)	2008-12-22	2014-12-10	Милленниум Фармасьютикалз, Инк.	Сочетание ингибиторов аврора киназы и анти-cd 20 антител
US20110319431A1 (en)	2009-03-12	2011-12-29	Biolipox Ab	Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
WO2010103279A1 (en)	2009-03-12	2010-09-16	Biolipox Ab	Bis aromatic compounds for use as lct4 synthase inhibitors
AR075835A1 (es)	2009-03-12	2011-04-27	Biolipox Ab	Compuestos bis-aromaticos para su uso como inhibvidores de ltc4 sintasa
US20120035217A1 (en)	2009-03-12	2012-02-09	Biolipox Ab	Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
US8546377B2 (en) *	2009-04-23	2013-10-01	Abbvie Inc.	Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en)	2009-04-23	2013-08-27	Abbvie Inc.	Modulators of 5-HT receptors and methods of use thereof
JO3635B1 (ar) *	2009-05-18	2020-08-27	Millennium Pharm Inc	مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) *	2009-07-31	2019-10-20	Millennium Pharm Inc	مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt)	2010-02-19	2018-01-02	Millennium Pharm Inc	formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
EP2545036A1 (en)	2010-03-12	2013-01-16	Biolipox AB	Bis aromatic compounds for use as ltc4 synthase inhibitors
AR086656A1 (es)	2011-06-03	2014-01-15	Millennium Pharm Inc	Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
GB201202027D0 (en) *	2012-02-06	2012-03-21	Sareum Ltd	Pharmaceutical compounds
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
CA2868302A1 (en)	2012-03-23	2013-09-26	Dennis M. Brown	Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103804391A (zh) *	2012-11-01	2014-05-21	韩冰	一类治疗神经退行性疾病的化合物及其用途
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN103408552B (zh) *	2013-07-25	2015-07-01	苏州明锐医药科技有限公司	阿立塞替的制备方法
EP3076963A4 (en)	2013-12-06	2017-09-13	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2017015316A1 (en) *	2015-07-21	2017-01-26	Millennium Pharmaceuticals, Inc.	Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2019195658A1 (en)	2018-04-05	2019-10-10	Dana-Farber Cancer Institute, Inc.	Sting levels as a biomarker for cancer immunotherapy
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
US20220305048A1 (en)	2019-08-26	2022-09-29	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
CN112062768B (zh) *	2020-07-20	2021-08-31	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	具有Aurora激酶降解活性的小分子及其制备方法和应用
JP2025503429A (ja) *	2021-12-14	2025-02-04	プレーザーセラピューティクスインコーポレイティド	ポリユビキチン化による標的タンパク質またはポリペプチドの分解用の新規化合物
WO2025087695A1 (en)	2023-10-23	2025-05-01	Ascend Advanced Therapies Ltd	Method for producing recombinant adeno-associated virus particles

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3947585A (en)	1974-06-03	1976-03-30	Ciba-Geigy Corporation	Pyrazolobenzazepines
US4022801A (en)	1974-06-03	1977-05-10	Ciba-Geigy Corporation	Pyrazolobenzazepines
US4028381A (en)	1975-05-05	1977-06-07	Ciba-Geigy Corporation	Pyrazolobenzazepines
US4099012A (en) *	1975-08-28	1978-07-04	Ciba-Geigy Corporation	2-pyrazolyl-benzophenones
NZ192803A (en)	1979-02-07	1984-08-24	Hoffmann La Roche	Pyrimido-2-benzazepines and pharmaceutical compositions
US4481142A (en) *	1979-02-07	1984-11-06	Hoffmann-La Roche Inc.	Pyrimido-2-benzazepines
ZA80492B (en) *	1979-02-07	1981-01-28	Hoffmann La Roche	Benzazepine derivatives
KR840000061B1 (ko)	1979-02-07	1984-01-31	에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트	벤즈아제핀 유도체의 제조방법
US4547581A (en)	1979-02-07	1985-10-15	Hoffmann-La Roche Inc.	Pyrimido-2-benzazepines and intermediates in their preparation
US4318854A (en)	1979-02-07	1982-03-09	Hoffmann-La Roche Inc.	Intermediates in the production of 2-benzazepines
US4469633A (en) *	1980-05-16	1984-09-04	Hoffmann-La Roche Inc.	N-oxides of 5-oxo-1-phenyl-2-benzazepines
NL8102182A (nl)	1981-05-04	1982-12-01	Philips Nv	Kleurenbeeldbuis.
EP0273697A3 (en)	1986-12-30	1989-11-29	Merck & Co. Inc.	2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en)	1988-03-25	1992-11-24	Merck & Co., Inc.	2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) *	1991-05-16	1993-05-11	Merck & Co., Inc.	2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5747487A (en)	1993-07-29	1998-05-05	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
EP0888350A1 (en)	1996-03-08	1999-01-07	Zeneca Limited	Azolobenzazepine derivatives as neurologically active agents
EP0946523A1 (en) *	1996-12-23	1999-10-06	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
ES2191963T3 (es)	1997-09-29	2003-09-16	Meiji Seika Kaisha	Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
US6277844B1 (en) *	1998-09-14	2001-08-21	Sydney Spector	Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en)	1999-05-12	2002-07-09	Nitromed, Inc.	Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
WO2002022605A1 (en) *	2000-09-15	2002-03-21	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) *	2000-12-21	2006-01-24	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en)	2001-05-18	2004-02-03	Hoffmann-La Roche Inc.	Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
JP4364637B2 (ja)	2001-08-09	2009-11-18	アクテリオンファーマシューティカルズリミテッド	新規なベンゾ縮合へテロ環化合物
CN1897950A (zh)	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
AU2005243175B2 (en) *	2004-05-14	2011-12-01	Millennium Pharmaceuticals, Inc.	Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CN101084214A (zh)	2004-11-17	2007-12-05	迈卡纳治疗股份有限公司	激酶抑制剂
WO2006070198A1 (en)	2004-12-30	2006-07-06	Astex Therapeutics Limited	Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CL2007003244A1 (es)	2006-11-16	2008-04-04	Millennium Pharm Inc	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en)	2007-11-27	2009-08-13	Abbott Laboratories	Method of treating cancer
JO3434B1 (ar) *	2009-07-31	2019-10-20	Millennium Pharm Inc	مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

2005
- 2005-05-12 AU AU2005243175A patent/AU2005243175B2/en not_active Expired
- 2005-05-12 ES ES10178391.8T patent/ES2540987T3/es not_active Expired - Lifetime
- 2005-05-12 EP EP13189935.3A patent/EP2719698B1/en not_active Expired - Lifetime
- 2005-05-12 PT PT05779921T patent/PT1771450E/pt unknown
- 2005-05-12 EA EA200602100A patent/EA012112B1/ru not_active IP Right Cessation
- 2005-05-12 PT PT07024446T patent/PT1905773E/pt unknown
- 2005-05-12 NZ NZ551370A patent/NZ551370A/en not_active IP Right Cessation
- 2005-05-12 WO PCT/US2005/016445 patent/WO2005111039A2/en not_active Ceased
- 2005-05-12 CN CN201410345955.0A patent/CN104193750B/zh not_active Expired - Lifetime
- 2005-05-12 ES ES05779921T patent/ES2299080T3/es not_active Expired - Lifetime
- 2005-05-12 MY MYPI20052151A patent/MY139355A/en unknown
- 2005-05-12 RS RS20080109A patent/RS50568B8/sr unknown
- 2005-05-12 PL PL05779921T patent/PL1771450T3/pl unknown
- 2005-05-12 KR KR1020067026332A patent/KR101792651B1/ko not_active Expired - Lifetime
- 2005-05-12 HR HRP20080120TT patent/HRP20080120T5/hr unknown
- 2005-05-12 CA CA2565411A patent/CA2565411C/en not_active Expired - Lifetime
- 2005-05-12 US US11/127,855 patent/US7572784B2/en active Active
- 2005-05-12 AT AT05779921T patent/ATE381566T1/de active
- 2005-05-12 BR BRPI0511139A patent/BRPI0511139B8/pt not_active IP Right Cessation
- 2005-05-12 EP EP05779921A patent/EP1771450B9/en not_active Expired - Lifetime
- 2005-05-12 DE DE602005003951T patent/DE602005003951T4/de not_active Expired - Lifetime
- 2005-05-12 ES ES07024446T patent/ES2391577T3/es not_active Expired - Lifetime
- 2005-05-12 KR KR1020127014200A patent/KR20120091275A/ko not_active Ceased
- 2005-05-12 DK DK05779921.5T patent/DK1771450T5/da active
- 2005-05-12 MX MXPA06013042A patent/MXPA06013042A/es active IP Right Grant
- 2005-05-12 JP JP2007513304A patent/JP4467616B2/ja not_active Expired - Lifetime
- 2005-05-12 RS RS20120416A patent/RS52436B/sr unknown
- 2005-05-12 KR KR1020137013571A patent/KR101748290B1/ko not_active Expired - Lifetime
- 2005-05-12 EP EP10178391.8A patent/EP2261226B1/en not_active Expired - Lifetime
- 2005-05-12 EP EP13189940.3A patent/EP2746285B1/en not_active Expired - Lifetime
- 2005-05-13 TW TW094115612A patent/TWI338688B/zh not_active IP Right Cessation
- 2005-05-16 AR ARP050102001A patent/AR049277A1/es unknown
2006
- 2006-11-06 IL IL179063A patent/IL179063A/en active IP Right Grant
- 2006-12-21 US US11/643,600 patent/US20070185087A1/en not_active Abandoned
2008
- 2008-03-17 CY CY20081100297T patent/CY1108092T1/el unknown
- 2008-05-08 JP JP2008122788A patent/JP5148358B2/ja not_active Expired - Lifetime
2009
- 2009-05-27 US US12/472,583 patent/US8399659B2/en active Active
2011
- 2011-09-16 JP JP2011203714A patent/JP2012006972A/ja not_active Withdrawn
2012
- 2012-10-02 HR HRP20120785TT patent/HRP20120785T1/hr unknown
- 2012-10-03 US US13/644,216 patent/US9102678B2/en not_active Expired - Lifetime
- 2012-10-16 CY CY20121100962T patent/CY1113192T1/el unknown
2014
- 2014-02-14 JP JP2014026015A patent/JP5827708B2/ja not_active Expired - Lifetime
2015
- 2015-07-27 US US14/810,225 patent/US9765078B2/en not_active Expired - Lifetime
2017
- 2017-09-18 US US15/707,484 patent/US10414770B2/en not_active Expired - Lifetime
2019
- 2019-09-13 US US16/569,809 patent/US11014928B2/en not_active Expired - Lifetime
2021
- 2021-05-24 US US17/328,618 patent/US20220041605A1/en not_active Abandoned
2023
- 2023-10-19 US US18/490,596 patent/US20240083906A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL179063A (en)	2016-05-31
US20220041605A1 (en)	2022-02-10
BRPI0511139A (pt)	2007-11-27
US20240083906A1 (en)	2024-03-14
CN104193750B (zh)	2018-04-27
TWI338688B (en)	2011-03-11
CA2565411A1 (en)	2005-11-24
US20160185782A1 (en)	2016-06-30
ES2391577T3 (es)	2012-11-27
EP2746285B1 (en)	2016-09-14
HK1199254A1 (en)	2015-06-26
CY1108092T1 (el)	2014-02-12
DE602005003951T4 (de)	2012-10-11
US9765078B2 (en)	2017-09-19
PT1771450E (pt)	2008-03-31
JP2014114319A (ja)	2014-06-26
HRP20080120T3 (hr)	2008-04-30
ES2540987T3 (es)	2015-07-15
EP2261226B1 (en)	2015-04-01
EP1771450B9 (en)	2008-12-24
AR049277A1 (es)	2006-07-12
US20070185087A1 (en)	2007-08-09
RS50568B (sr)	2010-05-07
KR101748290B1 (ko)	2017-06-16
KR20070011606A (ko)	2007-01-24
JP4467616B2 (ja)	2010-05-26
ES2299080T3 (es)	2008-05-16
EP1771450B1 (en)	2007-12-19
NZ551370A (en)	2009-08-28
US20090299060A1 (en)	2009-12-03
EP1771450A2 (en)	2007-04-11
KR101792651B1 (ko)	2017-11-20
EP2261226A1 (en)	2010-12-15
HK1114853A1 (en)	2008-11-14
US7572784B2 (en)	2009-08-11
JP5148358B2 (ja)	2013-02-20
US11014928B2 (en)	2021-05-25
ATE381566T1 (de)	2008-01-15
EA200602100A1 (ru)	2007-04-27
DK1771450T5 (da)	2012-01-09
DE602005003951T2 (de)	2008-12-11
JP2012006972A (ja)	2012-01-12
US20200247810A1 (en)	2020-08-06
US8399659B2 (en)	2013-03-19
PL1771450T3 (pl)	2008-05-30
WO2005111039A2 (en)	2005-11-24
EP2746285A1 (en)	2014-06-25
DK1771450T3 (da)	2008-04-28
CN104193750A (zh)	2014-12-10
HK1205102A1 (en)	2015-12-11
US20140046055A1 (en)	2014-02-13
AU2005243175A1 (en)	2005-11-24
TW200604192A (en)	2006-02-01
JP2008285484A (ja)	2008-11-27
PT1905773E (pt)	2012-10-25
JP5827708B2 (ja)	2015-12-02
RS52436B (sr)	2013-02-28
EA012112B1 (ru)	2009-08-28
KR20120091275A (ko)	2012-08-17
BRPI0511139B8 (pt)	2021-05-25
MXPA06013042A (es)	2007-02-12
HK1102500A1 (en)	2007-11-23
JP2007537268A (ja)	2007-12-20
IL179063A0 (en)	2007-03-08
KR20130073993A (ko)	2013-07-03
HRP20120785T1 (hr)	2012-11-30
US20180134716A1 (en)	2018-05-17
US9102678B2 (en)	2015-08-11
AU2005243175B2 (en)	2011-12-01
CY1113192T1 (el)	2016-04-13
US10414770B2 (en)	2019-09-17
EP2719698B1 (en)	2016-10-05
HRP20080120T5 (hr)	2012-07-31
MY139355A (en)	2009-09-30
EP2719698A1 (en)	2014-04-16
BRPI0511139B1 (pt)	2019-05-21
DE602005003951D1 (de)	2008-01-31
US20050256102A1 (en)	2005-11-17
WO2005111039A3 (en)	2006-04-20
CA2565411C (en)	2010-04-20
RS50568B9 (sr)	2019-06-28

Publication	Publication Date	Title
IL179063A0 (en)	2007-03-08	Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
EP1957078A4 (en)	2011-10-05	PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER BY INHIBITING AURORA KINASE
IL189933A0 (en)	2008-08-07	Rna antagonist compounds for the inhibition of apo-b100 expression
EP2121637A4 (en)	2010-10-06	ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
ZA200804253B (en)	2009-11-25	Method of inhibiting FLT3 kinase
SG10201503350TA (en)	2015-06-29	Compounds for inhibiting mitotic progression
GB2432165B (en)	2009-08-05	Method of inhibiting hydrate formation
ZA200704106B (en)	2009-09-30	Inhibitors of c-fms kinase
IL187257A0 (en)	2008-02-09	Compositions and methods for inhibition of the jak pathway
ZA201002438B (en)	2010-12-29	Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
AP2470A (en)	2012-09-17	Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
ZA200700826B (en)	2009-08-26	Thienopyrimidines useful as Aurora kinase inhibitors
IL182680A0 (en)	2007-09-20	Compositions and methods for short interfering nucleic acid inhibition of
IL172375A0 (en)	2009-02-11	Chinazoline derivatives as aurora kinase inhibitors
ZA200809874B (en)	2010-02-24	Method of inhibiting c kit kinase
IL182735A0 (en)	2007-09-20	Inhibitors of c-fms kinase
EP1778693A4 (en)	2009-11-11	AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
GB0608823D0 (en)	2006-06-14	Inhibitors of P13 kinase
SI1905773T1 (sl)	2013-01-31	Spojine in postopki za inhibiranje mitotične progresije z inhibiranjem aurora kinaze
EP1906967A4 (en)	2010-07-28	ABL Kinase Inhibition
PL1905773T3 (pl)	2012-12-31	Związki i sposoby hamowania progresji mitotycznej poprzez hamowanie kinazy aurora
EP1771203A4 (en)	2010-06-02	INHIBITION OF NF-KB
GB0410299D0 (en)	2004-06-09	Inhibition of biofilm formation
HK1131386A (en)	2010-01-22	Pyridobenzazepine compounds and methods for inhibiting mitotic progression
GB0621606D0 (en)	2006-12-06	Inhibitors of p13 kinase